Iron Mountain (IRM) continues to make significant moves in the bio-tech market. Notable highlights include the company's
Q1 2024 Earnings Call Transcript, showing promising profitability. The stock reached a
New 1-Year High at $82.31 but has seen minor fluctuations in recent times. The company has
exceeded Q1 Earnings expectations, yet some stakeholders like Victory Capital Management Inc and the Swiss National Bank have decreased their shares in Iron Mountain. The company's
Q1 dividends potentially justify investment as Iron Mountain seems poised for a profitable Q4 Earnings. On the insider front,
Director Wendy Murdock and General Counsel Deborah Marson made significant share sales. IRM also experienced significant growth in February with revenues and Earnings per share (EPS) maintaining a steady rise despite slight market lag. Mitsubishi UFJ Asset Management Co. Ltd grew its holdings while
Fisher Asset Management purchased 4478 shares. Key reasons to add IRM to your investment kitty include its
impressive yield and robust (AFFO) Adjusted funds from operations. While some investors have trimmed their stakes, others like First Trust Direct Indexing have increased their investment.
Iron Mountain IRM News Analytics from Tue, 22 Aug 2023 07:00:00 GMT to Sat, 18 May 2024 12:16:00 GMT -
Rating 7
- Innovation -3
- Information 5
- Rumor -2
